Colgate-Palmolive’s Price Target Boosted at Argus

• Colgate-Palmolive Company (NYSE:CL) reported earnings per share of $0.92 and net sales of $5.11 billion in Q2 2025.
• The company adjusted its full-year organic sales growth forecast to the lower end of the 2-4% guidance range.
• Colgate's stock experienced a slight decrease of approximately -0.47%, trading at $83.12.

Colgate-Palmolive Company (NYSE:CL) is a global leader in consumer products, specializing in oral care, personal care, home care, and pet nutrition. The company is known for its strong brand portfolio, including Colgate toothpaste and Palmolive dish soap. Colgate competes with other major consumer goods companies like Procter & Gamble and Unilever.

On July 31, 2025, Shelley Moore Capito was involved in a sale transaction of Colgate shares, owned by her spouse, valued between $1,001 and $15,000. This transaction was disclosed on August 4, 2025. Around this time, Colgate reported strong second-quarter 2025 results, with earnings per share of $0.92 and net sales of $5.11 billion, as highlighted by Seeking Alpha.

During the Colgate-Palmolive Q2 2025 earnings call on August 1, 2025, key executives, including John Faucher and Noel R. Wallace, discussed the company's financial performance and strategic initiatives. Colgate's pricing strategies contributed a 2% increase to organic growth, counterbalancing flat volume and foreign exchange-related sales pressures.

Despite these positive results, Colgate adjusted its full-year organic sales growth forecast to the lower end of its previous 2-4% guidance range. The company remains focused on enhancing its competitive edge by investing in digital, data, and analytics capabilities to drive profitability, as discussed during the earnings call.

Colgate's stock, trading at $83.12, has seen a decrease of 0.39, or approximately -0.47%, today. The stock's trading range for the day is between $82.40 and $84.00, with a market capitalization of approximately $67.36 billion. Over the past year, the stock has reached a high of $109.30 and a low of $82.40, reflecting the company's resilience amid economic pressures.

Colgate-Palmolive (NYSE:CL) is a well-known consumer products company, primarily recognized for its oral care, personal care, home care, and pet nutrition products. The company competes with other giants like Procter & Gamble and Unilever in the consumer goods sector. On April 25, 2025, CL reported impressive quarterly earnings, showcasing its strong market position.

CL reported earnings per share (EPS) of $0.91, surpassing the Zacks Consensus Estimate of $0.86. This marks an improvement from the $0.86 EPS reported in the same quarter last year. The company's revenue reached approximately $4.91 billion, exceeding the estimated $4.87 billion, highlighting its robust sales performance.

The company's price-to-earnings (P/E) ratio is around 26.13, indicating that investors are willing to pay $26.13 for every dollar of earnings. This suggests a positive market sentiment towards CL's future earnings potential. The price-to-sales ratio of 3.73 reflects the market's valuation of its revenue, while the enterprise value to sales ratio of 4.10 shows how the market values the company's total worth relative to its sales.

Colgate-Palmolive's enterprise value to operating cash flow ratio is approximately 20.04, providing insight into its valuation concerning cash generation. The earnings yield of about 3.83% offers a perspective on the return investors can expect. The company's debt-to-equity ratio of 40.15 indicates a balanced approach to financing its assets, while a current ratio of 0.92 suggests its ability to cover short-term liabilities with short-term assets.

• The consensus price target for Colgate-Palmolive Company (NYSE:CL) has been adjusted downwards, from $102.25 a year ago to $89 a month ago, reflecting a more conservative outlook from analysts.
• Despite inflationary pressures, Colgate-Palmolive reported a healthy profit margin of 14.4% and surpassed $20 billion in revenue in 2024.
• With a robust gross profit margin exceeding 60% and a return on total capital of 27.9%, Colgate-Palmolive is considered a strong defensive stock amidst recession concerns.

Colgate-Palmolive Company (NYSE:CL) is a global leader in consumer products, known for its strong brand presence in Oral, Personal, and Home Care, as well as Pet Nutrition. Despite its diverse product offerings, the consensus price target for CL has seen a downward adjustment over the past year, reflecting a more conservative outlook from analysts. A year ago, the average price target was $102.25, but it has since decreased to $89 a month ago.

The company's financial performance in 2024 was impressive, with revenue surpassing $20 billion, as highlighted by Benzinga. This success is attributed to Colgate-Palmolive's strong brand identity and operational discipline. Despite inflationary pressures, the company maintained a healthy profit margin of 14.4% and continued to invest in marketing and research and development, enhancing brand differentiation and price stability.

Analysts are closely watching Colgate-Palmolive's upcoming earnings report, with Jason English from Goldman Sachs setting a price target of $95 for the stock. Despite the downward adjustment in the consensus price target, the company demonstrates financial robustness with significant revenue and margin growth, generating record free cash flow. This positions Colgate-Palmolive well for the future, with a "Buy" rating and a target share price of $100.08 for 2025.

As concerns about a potential recession grow, investors are shifting towards more defensive stocks, with Colgate-Palmolive emerging as a strong candidate due to its non-cyclical nature. The company boasts a robust gross profit margin exceeding 60% and an impressive return on total capital of 27.9%, as highlighted by Seeking Alpha. Despite the conservative outlook, Colgate-Palmolive's stock is considered fairly valued, featuring a shareholder value yield that surpasses its historical average and a reasonable price-to-earnings ratio of 25.6x.

Colgate-Palmolive (NYSE:CL) is a well-known consumer products company, primarily recognized for its oral care, personal care, home care, and pet nutrition products. The company competes with other giants like Procter & Gamble and Unilever in the consumer goods sector. On April 25, 2025, CL reported impressive quarterly earnings, showcasing its strong market position.

CL reported earnings per share (EPS) of $0.91, surpassing the Zacks Consensus Estimate of $0.86. This marks an improvement from the $0.86 EPS reported in the same quarter last year. The company's revenue reached approximately $4.91 billion, exceeding the estimated $4.87 billion, highlighting its robust sales performance.

The company's price-to-earnings (P/E) ratio is around 26.13, indicating that investors are willing to pay $26.13 for every dollar of earnings. This suggests a positive market sentiment towards CL's future earnings potential. The price-to-sales ratio of 3.73 reflects the market's valuation of its revenue, while the enterprise value to sales ratio of 4.10 shows how the market values the company's total worth relative to its sales.

Colgate-Palmolive's enterprise value to operating cash flow ratio is approximately 20.04, providing insight into its valuation concerning cash generation. The earnings yield of about 3.83% offers a perspective on the return investors can expect. The company's debt-to-equity ratio of 40.15 indicates a balanced approach to financing its assets, while a current ratio of 0.92 suggests its ability to cover short-term liabilities with short-term assets.

• The consensus price target for Colgate-Palmolive Company (NYSE:CL) has been adjusted downwards, from $102.25 a year ago to $89 a month ago, reflecting a more conservative outlook from analysts.
• Despite inflationary pressures, Colgate-Palmolive reported a healthy profit margin of 14.4% and surpassed $20 billion in revenue in 2024.
• With a robust gross profit margin exceeding 60% and a return on total capital of 27.9%, Colgate-Palmolive is considered a strong defensive stock amidst recession concerns.

Colgate-Palmolive Company (NYSE:CL) is a global leader in consumer products, known for its strong brand presence in Oral, Personal, and Home Care, as well as Pet Nutrition. Despite its diverse product offerings, the consensus price target for CL has seen a downward adjustment over the past year, reflecting a more conservative outlook from analysts. A year ago, the average price target was $102.25, but it has since decreased to $89 a month ago.

The company's financial performance in 2024 was impressive, with revenue surpassing $20 billion, as highlighted by Benzinga. This success is attributed to Colgate-Palmolive's strong brand identity and operational discipline. Despite inflationary pressures, the company maintained a healthy profit margin of 14.4% and continued to invest in marketing and research and development, enhancing brand differentiation and price stability.

Analysts are closely watching Colgate-Palmolive's upcoming earnings report, with Jason English from Goldman Sachs setting a price target of $95 for the stock. Despite the downward adjustment in the consensus price target, the company demonstrates financial robustness with significant revenue and margin growth, generating record free cash flow. This positions Colgate-Palmolive well for the future, with a "Buy" rating and a target share price of $100.08 for 2025.

As concerns about a potential recession grow, investors are shifting towards more defensive stocks, with Colgate-Palmolive emerging as a strong candidate due to its non-cyclical nature. The company boasts a robust gross profit margin exceeding 60% and an impressive return on total capital of 27.9%, as highlighted by Seeking Alpha. Despite the conservative outlook, Colgate-Palmolive's stock is considered fairly valued, featuring a shareholder value yield that surpasses its historical average and a reasonable price-to-earnings ratio of 25.6x.

Argus analysts increased their price target on Colgate-Palmolive (NYSE:CL) to $107 from $97, while maintaining a Buy rating on the stock. The analysts praised Colgate-Palmolive as a well-established company with leading brands and expressed a positive outlook on the company's products that incorporate natural ingredients, as well as its new lines of pet food designed for younger pets and older pets with kidney issues. The company has consistently met or exceeded its long-term target for organic sales growth of 3%-5% over the past four years. Additionally, it has increased its dividend annually for over 60 years, currently offering a yield of approximately 2.1%.

Looking forward, the analysts expect Colgate-Palmolive to focus on enhancing its offerings of premium products, expanding online sales, leveraging analytics, and improving productivity. From a technical perspective, the stock has shown a bullish pattern of higher highs and higher lows since October 2023. On the valuation front, the stock trades at 25 times the analyst’s 2025 earnings per share (EPS) forecast, which is above the peer average of 23.

Given the company’s broadening product range and solid dividend track record, the analysts reiterate a Buy rating. The revised target price of $107 reflects a valuation multiple of 28 times the 2025 EPS estimate.